Immune-Stimulating Antibody Conjugates Targeting CEA & PD-L1 for Cancer Therapy

Time: 10:30 am
day: Day One


  • We have many good targets but no perfect ones – review some key steps to building a strong target validation package
  • Every target has a liability – understand what we can tolerate, what we should avoid, and when our assumptions should be put aside
  • Evaluate case studies including target validation for cytotoxic ADCs and immunotherapies